Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents

NCT01362322 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

671

Enrollment

INDUSTRY

Sponsor class

Conditions

Diphtheria
Tetanus
Acellular Pertussis

Interventions

BIOLOGICAL: Boostrix TM (new syringe presentation)
BIOLOGICAL: Boostrix TM (previous syringe presentation)

Sponsor

GlaxoSmithKline